X

Power Law company profile

Xoft

Biotech & Life Sciences · San Jose, United States · Founded 1998

Xoft, founded in 1998 and initially based in Sunnyvale, California, operates in the oncology and medical device market, specializing in electronic brachytherapy (eBx). The company has undergone significant corporate changes, including an acquisition by iCAD, Inc. in late 2010 for approximately $13.1 million, and was subsequently acquired by Elekta in October 2023 for about $5.5 million plus assumed liabilities. This latest acquisition positions Xoft within Elekta's extensive global network, aiming to expand the adoption of its technology. The core of Xoft's business is the Axxent® Electronic Brachytherapy (eBx®) System®. This system represents a significant shift from traditional radiation therapy by utilizing a proprietary, miniaturized, low-energy X-ray source instead of radioactive isotopes. This distinction is crucial as it eliminates the need for heavily shielded treatment rooms, reduces radiation exposure to surrounding healthy tissue, and circumvents the logistical challenges and costs associated with handling radioactive materials. The system's mobility allows it to be used in various clinical settings, including standard exam rooms and operating rooms, without requiring major construction investments. Xoft's primary clients are hospitals, cancer treatment centers, and radiation oncology practices. Its business model centers on the sale of the Axxent eBx System and its associated applicators and accessories. The system is FDA-cleared and CE-marked for treating cancer anywhere in the body. Its main applications include treating non-melanoma skin cancer, early-stage breast cancer, and gynecological cancers. For skin cancer, it offers a painless, non-invasive alternative to surgery. In breast cancer treatment, the system facilitates Intraoperative Radiation Therapy (IORT), where a single, targeted dose of radiation is delivered in minutes at the time of lumpectomy, drastically shortening treatment duration compared to the traditional six to eight-week external beam radiation therapy. The technology is also being applied to other areas, including colorectal, prostate, and brain cancers. Keywords: electronic brachytherapy, radiation oncology, medical device, cancer treatment, IORT, isotope-free, Axxent System, non-melanoma skin cancer, gynecological cancer, breast cancer